Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma

Annals of Surgical Oncology

Volumn 11, Issue 5, 2004, Pages 491-499

  Noorda, Eva M ^a   Takkenberg, Bart ^a   Vrouenraets, Bart C ^a   Nieweg, Omgo E ^a   Van Geel, Bert N ^b   Eggermont, Alexander M M ^b   Hart, Guus A M ^a   Kroon, Bin B R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Extremities; Local recurrences; Melanoma; Regional perfusion

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ACUTE TOXICITY; ADULT; AGED; ARM; ARTICLE; BLISTER; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; FOOT; HUMAN; INTERMETHOD COMPARISON; LIMB PERFUSION; LOWER LEG; MALE; MELANOMA; METASTASIS; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; THIGH; TISSUE NECROSIS; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; REGIONAL PERFUSION; SKIN TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 3242782681     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.04.032     Document Type: Article

References (31)

1. Lejeune FJ, Lienard D, el Douaihy M, Seyedi JV, Ewalenko P. Results of 206 isolated limb perfusions for malignant melanoma. Eur J Surg Oncol 1989;15:510-9.
2. McMasters KM. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:939-40.
3. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996;83:509-12.
4. Strobbe LJ, Nieweg OE, Kroon BB. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 1997;23:435-8.
5. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996;83:1319-28.
6. Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906-12.
7. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991;9:2091-4.
8. Fraker DE, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-89.
9. Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Seminin Oncol 2002;29:400-9.
10. Klaase JM, Kroon B, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994;178:564-72.
11. Kroon B. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988;14:101-10.
12. Kroon B, Klaase J, van de Merwe SA, van Dongen J, van der Zee J. Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study. Regional Cancer Treatment 1992:305-8.
13. Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the Limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
14. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
15. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.
16. Lee LW, Wei LJ, Amato D. Cox-type regression analysis for large number of small groups of correlated failure time observations. In: JP Klein and PK Goel (ed.) Survival analysis, state of the art. Netherlands: Kluwer Academic Publishers; 1992:237-47.
17. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association 1989;84:1065-73.
18. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
19. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
20. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-9.
21. Hwu WJ. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology (Huntingt) 2000;14:25-8.
22. Noorda EM, Vrouenraets BC, Nieweg OL, et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968-74.
23. Fraker D, Alexander H, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. In: SSO 55th Annual Cancer Symposium 2002;S8.
24. Feldman AL, Alexander Jr HR, Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999;6:562-7.
25. Lejeune FJ, Deloof T, Ewalenko P, et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 1983;86:268-76.
26. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115:39-45.
27. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989;63:2551-61.
28. Vrouenraets BC, Hart GA, Eggermont AM, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999;188:522-30.
29. Vrouenraets BC, Eggermont A, Klaase J, et al. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol 1994;20:681-5.
30. Vrouenraets BC, in't Veld GJ, Nieweg OE, et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999;25:503-8.
31. van Geel AN, van Wijk J, Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989;63:1092-6.